Sharon Hashmueli

Sharon has served as Biond’s VP of Regulatory Affairs & CMC since its inception. She has over 15 years of experience in CMC and regulatory product development of biologics (pre-IND, IND, CTA, and NDA) including recombinant proteins and antibodies. Prior to Biond, Sharon was VP Regulatory and Clinical Affairs of cCAM Biotherapeutics (acquired by Merck) developing a novel immune checkpoint inhibitor for cancer. Beforehand at Protalix Biotherapeutics, she played a significant role in the development of Elelyso, an FDA approved treatment for Gauche disease marketed by Pfizer. Sharon holds a Ph.D. in Biotechnology and Food Engineering from the Technion – Israel Institute of Technology.